All In Biotech

NDA 021272 · United Therap

Remodulin

Treprostinil · Intravenous, Subcutaneous · Prostacycline Vasodilator

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

May 21, 2002

Approved uses

3

Original approval plus efficacy supplements

Registered trials

129

42 Phase 3, 15 recruiting

FAERS reports

65,346

41,979 serious, 9,061 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 2, 2026.

Remodulin is a prostacyclin mimetic indicated for: Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1) ] . 1.2 Pulmonary Arterial Hypertension in Patients Requiring Transition from Epoprostenol In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

Mechanism: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 20, 2006 Supplement 5 · Efficacy · priority review LabelReviewLetter
  • Nov 24, 2004 Supplement 2 · Efficacy Review
  • May 21, 2002 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
8 products under this application
  • REMODULIN · TREPROSTINIL 0.2MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 20MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 5MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
  • REMODULIN · TREPROSTINIL 1MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
  • REMODULIN · TREPROSTINIL 0.4MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • REMODULIN · TREPROSTINIL 0.1MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 10MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
  • REMODULIN · TREPROSTINIL 2.5MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea9,904
  • headache7,178
  • diarrhoea6,904
  • nausea6,212
  • infusion site pain5,788
  • death5,236
  • fatigue4,101
  • dizziness3,852
  • vomiting3,407
  • infusion site erythema3,353
  • pain in extremity2,976
  • hypotension2,834

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200435
200562
200688
200743
200836
200971
2010900
20111,625
2012657
20131,002
20144,603
20155,481
20164,840
20174,855
20185,311
20194,970
20204,272
20214,041
20224,380
20235,081
20244,633
20254,928
20263,432

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Remodulin (Treprostinil Sodium)

2024 spending

$13.5M

Beneficiaries

110

1,228 claims

Per beneficiary

$122,999

$437.45 per unit

View as table
YearSpending
2020$5,233,310
2021$6,905,569
2022$10,337,855
2023$11,819,879
2024$13,529,903

Part B: Remodulin* (Treprostinil Sodium*) · HCPCS J3285

2024 spending

$122M

Beneficiaries

909

12,831 claims

Per beneficiary

$133,774

2024 ASP limit $55.56 per unit

View as table
YearSpending
2020$163,468,435
2021$155,903,548
2022$130,449,989
2023$126,521,237
2024$121,601,006

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: United Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.